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The possibility of enhancing aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) by simultaneous application of localised
hyperthermia (HT) was evaluated. Treatments of rat DS-sarcomas included: (i) control, (ii) ALA administration (375mgkg
 1, i.p.), no
illumination, (iii) ‘nonthermal’ illumination, (iv) ALA-PDT: that is, ALA administration, ‘nonthermal’ illumination, (v) localised HT, 431C,
60min (vi) ALA-PDTþHT: ALA administration with full spectrum irradiation resulting in ALA-PDT and HT. Tumour volume was
monitored for 90 days or until a target volume (3.5ml) was reached. No differences were seen between the first three groups, with
all tumours reaching the target volume by 8–11 days. A total of 13 and 15% of tumours did not reach the target volume by day 90
following HT or ALA-PDT treatment, respectively. ALA-PDTþHT showed the greatest antitumour effect (P¼0.0001), with 61% of
the tumours not reaching the target volume. Viability and in vitro growth were also assessed in cells from tumours excised after
treatment. ALA-PDTþHT reduced the fraction of viable tumour cells by 85%, and in vitro culture showed pronounced growth delay
compared to control cells. These results demonstrate an enhanced antitumour effect upon ALAþHT, which appears to involve
direct cell toxicity rather than solely vascular damage.
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Photodynamic therapy (PDT) is a cancer treatment based on the
photosensitisation of tumour cells and exposure to light with
subsequent death of the malignant cells. One approach uses a
natural porphyrin precursor, 5-aminolaevulinic acid (ALA), which
enters the endogenous haem synthesis pathway. The final step in
this pathway involves the incorporation of iron into protopor-
phyrin IX (PpIX) to produce haem. Due to the fact that many
tumours exhibit abnormal levels of some of the enzymes involved
in this pathway, a selective accumulation of PpIX – which is an
efficient photosensitiser – can occur in tumour cells (Peng et al,
1997). PDT with ALA has been the focus of much clinical research
and ALA is emerging as a promising agent for photodynamic
treatment of lesions of the skin and internal hollow organs (Peng
et al, 1997; Kelty et al, 2002). While PDT with ALA shows a
number of advantages, such as reduced skin phototoxicity in
comparison to other photosensitisers, its effect is usually super-
ficial, a factor which may limit its clinical applicability. A number
of investigations have been carried out to enhance the effects of
ALA-PDT and have included the use of varying fluence rates and
light fractionation (Messmann et al, 1995; de Bruijn et al, 1999;
Iinuma et al, 1999), iron chelators (Curnow et al, 1998) and the use
of ALA-esters (Peng et al, 1997). Other antitumour approaches
include the combination of PDT with radiotherapy (Peng et al,
1997; Allman et al, 2000) or chemotherapy (Datta et al, 1997; Canti
et al, 1998). Evidence is also available suggesting that the
combination of PDT with hyperthermia (HT) may result in
enhanced tumour response effects. In a number of in vitro studies,
the combination of HT and PDT resulted in synergistic effects
(Christensen et al, 1984; Mang and Dougherty, 1985; Rasch et al,
1996). Investigations carried out in vivo also showed promising
effects (Henderson et al, 1985; Levendag et al, 1988; Kimel et al,
1992; Chen et al, 1996), although a thorough assessment of the
optimum sequencing of the therapy components – especially in
terms of a simultaneous application – has proven to be technically
difficult. Waldow et al (1984) stated that although it may be
desirable to carry out heat and light delivery simultaneously, they
were prevented from doing this because of the practical limitations
of using a microwave applicator for HT together with a laser for
photosensitiser activation. From a clinical point of view, a therapy
combination that could be applied in a single session would
certainly be favourable. At the same time, consideration should
also be given to the fact that the high costs of often complex laser
systems probably represent the biggest obstacle to PDT gaining
widespread clinical acceptance (Stringer, 1995). In the present
study, an easily applicable technique has been used for simulta-
neous localised HT and ALA-based PDT using a single, nonlaser
radiation source (Kelleher et al, 1999) in a rat tumour model. The
experiments were designed to look at tumour growth in vivo and
in vitro following treatment and to clearly elucidate the effects of
the individual therapy components alone and in combination.
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sMATERIALS AND METHODS
Animals and tumours
The DS-sarcoma tumour growing in male Sprague–Dawley rats
(Charles River Wiga, Germany; receiving a standard diet and
water ad libitum, body weight at the time of tumour implantation:
180–210g) was used in all experiments. Solid tumours grew
subcutaneously following injection of DS-sarcoma ascites cells
into the hind foot dorsum (0.4ml; approx. 10
4cellsml
 1). This
tumour was originally chemically induced in rats and arose in
the auditory canal (Vaupel, 1974). Experimentation had previously
been approved by the regional Ethics Committee, and was
conducted according to the German Law for Animal Protection
of 1987.
Photosensitiser
5-Aminolaevulinic acid (Sigma, Germany) was dissolved
in phosphate-buffered saline (PBS) at a concentration of
80mgml
 1. This solution was slowly injected into a tail vein 3h
before illumination so that the animals received a dose of
375mgkg
 1 ALA (injection volume per rat E1ml). After ALA
injection, the animals were kept under subdued lighting conditions
until treatment commenced. An equivalent volume of PBS was
administered to control animals. The ALA dose was chosen on the
basis of preliminary experiments, showing this dose to be the most
effective in terms of tumour growth inhibition in combination with
low toxicity. These experiments also showed this dose to be the
lowest possible ALA concentration resulting in maximum ALA-
induced fluorescence in the tumour investigated.
Treatments
Once a tumour volume of 0.6–0.8ml had been attained (6–8 days
after tumour implantation), the animals were anaesthetised with
sodium pentobarbital (40mgkg
 1 i.p., Narcoren
s, Merial, Ger-
many) and randomly allocated to the various experimental groups,
the details of which are summarised in Table 1.
A radiation delivery system was used which has been described
in detail previously (Vaupel et al, 1992; Kelleher et al, 1995, 1999).
The light source in this system is a halogen lamp (24V/150W, type
HLX64643, Osram, Germany) that emits over the spectral range
from 420 to 1400nm. The methods for activating the photo-
sensitising drug or for inducing localised tumour HT were based
on the same protocol. Since light fractionation and fluence rate can
both affect the PDT tumour response, these parameters were
carefully controlled, as described below. Additionally, since an
‘unconventional’ light fractionation was used for PDT in this
study, further experiments were carried out that compared this
fractionation with continuous light. Here, treatment with contin-
uous light was carried out with the same drug and light dose as for
the fractionated treatment (see Table 1, Group IV), except that the
light was administered continuously over 30min. As described
above, the experimental groups were treated with light of different
wavelengths. For groups III and IV, where ‘nonthermal’ illumina-
tion was required, a short wave-pass filter was inserted into the
radiation path to remove wavelengths 4800nm, so that the
infrared bands which would otherwise result in heating were
removed. The full spectral range (420–1400nm) was applied in
those groups receiving HT (i.e., groups V and VI). Another feature
of the light delivery system is a water-filter that is built in
as a closed cuvette (Hydrosun, Germany) and is responsible
for two strong, distinct absorption bands at 944 and 1180nm
which, when unfiltered are absorbed by the most superficial
skin layers and can lead to painful sensations and exsiccosis.
The water-filtered infrared component allows (at the same
radiant flux density on a given surface) for longer exposure
times and higher heat doses. Therapeutically relevant heating
of tissue layers at a depth of up to 1.2cm has been found to
be possible with this system and the pattern of temperature
gradients achieved has been described (Vaupel et al, 1992;
Kelleher et al, 1995). The application of HT in this study (groups
V and VI) involved the additional use of a feedback control
system, where the temperature in the tumour centre was measured
with needle-type thermocouples (f 250mm; type 2ABAc, Philips,
Germany) and the tumours heated at a rate of 0.41Cmin
 1 to
a set temperature of 431C (tumour centre) using the radiation
source. Following a 20min heat-up phase, the tumour temperature
was maintained at this set level for 60min, by continuous
regulation of the source that switched on and off intermittently
(total illumination time¼80min). This resulted in an average
effective total energy dose of 1120Jcm
 2 over the treatment
period as measured in pilot studies. These pilot studies, in which
HT was applied were also used to obtain information concerning
the pattern of irradiation with the light delivery system used.
An evaluation of these studies showed that, on average, tumours of
the volume used in the present study were irradiated for a period
of 1.3s followed by a nonillumination period of 2s, with this
pattern continuing over the 80min illumination period. This
pattern was subsequently used for the groups requiring ‘non-
thermal’ illumination so that the light delivered in the range from
420 to 800nm was equal for all the illuminated groups, with a
fluence rate of 200mWcm
 2 over this wavelength range for all
treated groups. Additionally, the light hyperfractionation schedule
was the same for all groups receiving irradiation. Light dosimetry
was performed using a calibrated radiometer/photometer
(IL1400A, International Light, USA). Irradiation was applied solely
to the tumour, the remainder of the animal being shielded by
aluminium foil.
On considering the treatment data outlined in Table 1, the
fluence rate and light dose administered may appear high in
comparison to that conventionally used during PDT. It should,
however, be remembered that these parameters were not selected
solely with PDT treatment in mind, but arose from the energy
doses necessary to induce 431C HT and the properties of the light
source used. Lower fluence rates, at least for the ALA-PDT group,
would have made a direct comparison between the different
treatment groups inappropriate since identical fluence rates in the
different groups for the wavelength ranges used would not have
been applied.
Table 1 Description of parameters for the treatment groups
Group no. Treatment
ALA dose
(mgkg
 1, i.v.)
Drug – illumination
interval (h)
Wavelength
range (nm)
Fluence rate
(mWcm
 2)
Total energy
dose (Jcm
 2)
Duration of
illumination (min)
I Control — — — — — —
II ALA-dark 375 — — — — —
III Light alone — — 420–800 200 370 80
IV ALA-PDT 375 3 420–800 200 370 80
V HT — — 420–1400 600 1120 80
VI ALA-PDT+HT 375 3 420–1400 600 1120 80
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sAssessment of tumour response in vivo
Prior to and following treatment, the three orthogonal diameters
(d) of the tumours were measured on a daily basis and the tumour
volume (V) was determined using the ellipsoid approximation
V¼p/6 d1 d2 d3. In accordance with the guidelines of the
UKCCCR (Workman et al, 1998), a target volume of 3.5ml
(selected so that the tumour burden by the end of the study never
exceeded 1% of the animal’s body weight) was used as the end
point for the tumour growth study rather than survival. Where the
tumour volume did not reach the target volume, the animals were
monitored for up to 90 days.
Assessment of tumour response in vitro
In a second series of experiments, tumours were treated in vivo
and thereafter excised under sterile conditions, minced using a
scalpel blade, and pressed through a cell dissociation sieve (380mm
pore size, Sigma) using a glass pestle. A single-cell suspension was
then prepared by incubating the tissue clumps in 30ml culture
medium (RPMI1640 (Sigma), supplemented with 10% bovine calf
serum (HyClone, USA)) with 2ml of an enzyme mixture contain-
ing 0.4mgml
 1 DNAase (Roche, Germany) and 0.05mgml
 1
collagenase (Sigma) for 20min at room temperature, after which
the cells were dispersed by repeated passage through a 22 gauge
needle. Finally, the cells were washed, centrifuged and resuspended
in culture medium (RPMI supplemented with calf serum as above).
The cell number was then assessed in a haemocytometer, and cell
viability determined by trypan blue exclusion (tumour cells from
this cell line can be easily identified due to their characteristically
large size). The cells were then decanted into tissue culture flasks at
an initial concentration of 50000 vital cells per millilitre growth
medium, where they grew as a suspension in a humidified
atmosphere of 5% CO2 in air for up to 6 days in the dark. The
number of vital tumour cells was re-evaluated on a daily basis in a
haemocytometer.
Determination of ALA-induced fluorescence by flow
cytometry
In order to assess differences in PpIX accumulation between
tumour tissue and normal tissues, tumour-bearing animals were
injected with ALA or PBS as described above. At 3h after injection,
tumours and normal tissues (liver, kidney, spleen) were excised
and mechanically dispersed to obtain a single-cell suspension.
Flow cytometric measurements were performed using an EPICS
XL-MCL system (Beckman-Coulter, USA) to determine ALA-
induced fluorescence. For this, the cells were illuminated by an
argon laser (wavelength 488nm) and the mean fluorescence was
assessed in the wavelength range 605–635nm. Tissues of animals
receiving PBS served as controls and ratios between ALA-treated
and control tissues were calculated.
Statistical analysis
In vivo tumour growth characteristics were calculated using
Kaplan–Meier statistics and the significance of the differences
between the various groups was assessed using a log-rank analysis.
All other analyses were carried out using the Wilcoxon test for
unpaired samples. The significance level in all cases was set at
a¼5%.
RESULTS
Following treatment, animals from all groups were found to
recover rapidly, with no side effects on general well-being or
phototoxic effects on normal skin being recorded. Tumour size
was assessed either until a tumour volume of 3.5ml was attained
(at which point animals were humanely killed) or up until 90 days
after treatment. The probability of the tumour volume being less
than 3.5ml at any time point during the study was calculated using
a Kaplan–Meier analysis (Figure 1). On comparing the control
group with the ALA-dark or light alone groups, no significant
differences were found, with all tumours reaching the target
volume by approx. 10 days after treatment. Tumour treatment with
either ALA-PDT or HT alone caused a significant increase in the
probability of tumours not reaching the target volume compared
to the control group (P¼0.0001, in both cases). Although the
probability of not reaching the tumour target volume 90 days after
treatment was approx. 15% in the case of either ALA-PDT or HT
treatment, the log-rank test showed the course of the curves from
these two treatment groups to be significantly different
(P¼0.0006), with the ALA-PDT group demonstrating an enhanced
tumour growth delay up to 30 days following treatment, as seen in
the corresponding right-shift in the early phase of the Kaplan–
Meier curve. Treatment of tumours with ALA-PDTþHT produced
the most pronounced antitumour effect, with a probability of the
tumour not reaching 3.5ml by 90 days after treatment of 61%, an
effect which was significantly greater than that seen in the control,
HT and ALA-PDT treatment groups (Po0.0001, in all cases). Of
the animals monitored till 90 days in the ALA-PDTþHT group,
none showed any evidence of tumour presence on macroscopic
examination. The combined treatment therefore produces an
antitumour effect which appears to be more than additive in
comparison to the two component treatments alone. It is
important to note that the assessment of true synergism, as
described by Steel and Peckham (1979), was not within the scope
of this study since it would require dose–response curves for both
the therapy components. During ALA-PDT, the mean tumour
temperature rose from 36.270.21C( n¼25) prior to the treatment
to 37.670.161C (175 temperature measurements) during the
treatment, with a peak temperature of 38.470.12 (n¼25). These
temperatures are within the normal physiological range for rat
rectal temperatures and therefore an HT component in the ALA-
PDT treatment is unlikely. Experiments comparing the effects of
fractionated and continuous light delivery schedules in ALA-PDT
treatment showed no significant difference on log-rank analysis,
with the probability of the tumour not reaching the target volume
of 14.5% (n¼25) by 90 days with the fractionated light schedule
and 15% (n¼11) with the continuous light schedule. Thus an
influence of light fractionation on the PDT effect in this setting can
be ruled out.
In further experiments in which tumours were excised
immediately after treatment, the degree of cell viability was
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Figure 1 Kaplan–Meier analysis showing the probability of tumour
volume being less than 3.5ml as a function of time after control (sham-
treatment), light alone, ALA-dark, HT (431C, 60min), ALA-PDT or
combined ALA-PDTþHT treatment. n¼number of animals treated.
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sassessed (Figure 2). When compared to control tumours, HT or
ALA-PDT treatments significantly reduced the fraction of surviv-
ing vital cells, by 31 and 67%, respectively, with an even greater
effect being seen following ALA-PDTþHT, where 86% of the
tumour cells were no longer viable (Po0.005). Subsequently, the
growth of viable cells from tumours of the different treatment
groups was monitored in vitro (Figure 3). In cells from control
tumours, a doubling time of 0.75 days was calculated from the
growth curves over the exponential growth phase, which was
prolonged to 0.86, 0.93 and 1.24 days for cells from ALA-PDT, HT
and ALA-PDTþHT treated tumours, respectively. When the
numbers of cells on day 4 following treatment and excision were
compared, all treatment groups had a significantly lower number
of cells than the control group, and, in the case of the combined
treatment, the cell number was significantly lower than with either
of the component treatments (Po0.01, in all cases).
Results from the assessment of ALA-induced fluorescence are
shown in Figure 4. Tissues were excised 3h after ALA adminis-
tration and the extent of ALA-induced fluorescence was assessed.
Control tissues were obtained from animals treated with PBS so
that treatment/control ratios for each tissue type could be
determined. The greatest accumulation of fluorescence was found
in tumour cells, where more than six times the amount of
fluorescence was measured compared to control tumour tissue.
Although the method used cannot exclude the contribution of
other cell types within the tumour mass and will additionally not
register any fluorescent products accumulating in the tumour
interstitium, it would appear that DS-sarcoma cells are capable of
accumulating ALA and converting it into fluorescent substances to
a greater extent than the normal tissues studied. One of the
fluorescent products of ALA metabolism is PpIX, which is thought
to be predominantly responsible for the ALA-induced photo-
dynamic effect. Ideally, in order to show selectivity of ALA uptake
and conversion to fluorescent products in tumour tissue, a
comparison of the uptake in normal skin and tumour in ALA-
treated animals would have been appropriate. However, the
mechanical dispersion of skin to obtain the required single-cell
suspension was not possible, and an enzymatic dispersion would
have required a moderate incubation period, thus not allowing
determination of fluorescence 3h after ALA administration. Here,
a recent study by Perotti et al (2002) is noteworthy, which
examined porphyrin synthesis using spectrofluorometry following
ALA administration and found a similar tumour to liver ratio (1.3)
to that reported here (1.1). At the same time, they obtained a
tumour to skin ratio of 2.94. Assuming that the skin uptakes in the
two studies are comparable, the results would appear to suggest a
selective uptake of and conversion of ALA by the DS-sarcoma used
in the present study, which may reflect tumour-specific differences
in the haem metabolic pathways and/or differences in ALA uptake.
DISCUSSION
Although HT alone is not considered an adequate therapy form for
the curative treatment of human tumours, a number of clinical
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Figure 2 Cell viability following treatment with HT (431C, 60min), ALA-
PDT or combined ALA-PDTþHT treatment, expressed relative to the
values found in control (sham-treated) tumours. The values are means
7s.e.m., and the number of tumours investigated is indicated at the base of
the columns. The significance levels indicate differences between control
and treatment groups or between treatment groups as indicated.
**Po0.005, *Po0.05.
Control
HT
ALA-PDT
ALA-PDT + HT
10
8
6
4
2
0
0123456
Time after treatment (days)
Cell n
umber ml
−1
 medium (×10
5
)
Figure 3 Tumour cell number as a function of time following in vivo
treatment. A single-cell suspension for in vitro culture was prepared
immediately after treatment from tumours undergoing sham-treatment
(control), HT (431C, 60min), ALA-PDT or combined ALA-PDTþHT
treatment. Each data point represents means7s.e.m. obtained with cells
excised from a minimum of six tumours.
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Figure 4 Mean fluorescence (at 605–635nm) in tumour and normal
tissues as determined by flow cytometry. Tumour-bearing animals were
injected with ALA (375mgkg
 1, dissolved in PBS 80mgml
 1)o r
equivalent volumes of PBS. After 3h, single-cell suspensions from tissues
of interest were obtained and ALA-induced fluorescence was measured by
flow cytometry. Ratios between ALA-treated and control tissues were
calculated and are shown in the shaded bar. The values shown are
means7s.e.m. with the number of samples at the bases of the columns.
Significance levels from differences between tissues obtained from ALA-
treated and control animals; ***Po0.001, **Po0.01, *Po0.05.
Combined ALA-based photodynamic therapy and hyperthermia
DK Kelleher et al
408
British Journal of Cancer (2003) 89(2), 405–411 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sstudies have demonstrated a clear benefit when HT is combined
with other therapy modalities, in particular radiotherapy (Over-
gaard et al, 1996; Vernon et al, 1996; Prosnitz et al, 1999; van der
Zee et al, 2000). A number of experimental studies, both in vitro
and in vivo have also suggested a possible role for HT in
combination with PDT, a therapy form that is currently being
applied to a number of malignant and nonmalignant conditions
(Ackroyd et al, 2002). In in vitro studies, the photodynamic
process was found to be inherently temperature dependent
(Gottfried and Kimel, 1991), and in a range of normal and tumour
cell systems, the combination of HT and PDT was invariably found
to be additive, if not synergistic, in terms of its cytotoxic effect
(Christensen et al, 1984; Mang and Dougherty, 1985; Chen et al,
1996; Rasch et al, 1996). Most of these studies focused on
identifying an optimal time interval between the two therapy
components, and generally found that HT followed by PDT led to
additive effects, whereas PDT followed closely by HT produced
greater than additive effects, suggesting that in this sequence, the
two modalities interact in a manner to induce cytotoxicity which is
greater than the sum of the individual treatments. A similar
pattern was found in in vivo experimental studies. Henderson et al
(1985) examined the effects of photofrin-based PDT using a laser
for photoactivation in combination with microwave-induced HT in
RIF-mouse tumours. In these animals, PDT followed by HT
showed the greatest inhibition of in vivo tumour growth and
reduction of in vitro clonogenicity of cells taken from these
tumours after treatment, which was seen to be potentiated when
compared to the individual treatments. Other groups reported
similar results, and explained that due to practical limitations (e.g.,
the use of a laser for photoactivation together with the use of a
microwave to induce heating), simultaneous PDT and HT could
not be carried out, even though this may be desirable when
considering application in the clinical setting (Waldow et al, 1984,
1985; Levendag et al, 1988; Chen et al, 1996). In a study using a
very elaborate technical set-up involving both an argon-dye laser
(for photoactivation) and a neodymium:yttrium-aluminium-
garnet laser (for heat deposition), a simultaneous application
could be carried out and an enhanced tumour cure seen (Mang,
1990).
The issue of HT in PDT treatment has been frequently discussed
in the past. The conclusions drawn from many ‘PDT’ studies, in
which high fluence rates were often used, were confounded
because of tissue heating during therapy. Kinsey et al (1983)
mentioned that many reports attributing cell killing solely to PDT
are probably only partially correct, and that in many instances, the
tissue heating induced will have contributed to the tumoricidal
effect. An exact determination of the role of HT in PDT studies is
difficult due to the fact that the rise in temperature during PDT is
dependent on a number of variable parameters, including optical
absorption and light scattering, exposure time, tissue properties,
thermal conduction and tumour perfusion (Svaasand et al, 1983).
One study – in which attempts were made to quantify heating in
hamster tumours during PDT – documented temperatures of over
431C in tumours and concluded that an unrecognised overlap of
the effects of PDT and HT might complicate the interpretation of
studies on the mechanisms underlying PDT (Leunig et al, 1994).
Certainly, uncontrolled and unmonitored tissue heating may not
be a reasonable option for enhancing the PDT effect since there
appears to be a narrow temperature window for this enhancement.
Waldow et al (1984) reported the absence of any tumour control
enhancement at ‘sublethal’ temperatures (p39.51C), but an
enhancement at temperatures of between 40.5 and 44.51C. Rasch
et al (1996) found that the degree of synergism depended greatly
on the temperature reached, with effects at 431C being greater than
at 491C. In a colon carcinoma model, the effect of ALA-PDT was
seen to be enhanced by HT at 40.51C, which was chosen to mimic
temperature elevations frequently seen during ALA-PDT in clinical
studies. This combined treatment led to a slower tumour growth
(monitored for 14 days) and greater tumour necrosis than that
seen with the treatment components alone.
The aim of the present study was to use an easily applicable
single, nonlaser radiation source enabling a simultaneous combi-
nation of HT and ALA-PDT, whereby the HT component was
regulated to maintain a clearly defined and controlled pattern of
tumour heating set at 431C. While the irradiation source used has
been previously described, this study has now identified the effects
of HT and PDT alone, showing that the effects of the combined
therapy were considerably greater than the effects of the sum of the
individual components, which may indicate a synergistic interac-
tion. The combined therapy resulted in complete tumour cure in
over 60% of the tumours treated (assessed by macroscopic
examination for up to 90 days following treatment), which was
considerably greater than that achieved in a mouse colon
carcinoma model with a lower temperature of 40.51C, where only
a growth delay was seen (Orenstein et al, 1999). As far as the
applicability of this combined treatment in the clinical setting is
concerned, the technical features of the irradiation source used
would allow treatment of superficial lesions, including cutaneous
or subcutaneous metastases and accessible mucosal tumours.
Delivery of light to more inaccessible regions can also be envisaged
with the use of fibre optic technology. Further experiments – in
which tumour cell viability and growth in vitro were assessed
following in vivo treatment – were designed to provide an
indication of possible mechanisms underlying the combined
treatment effects. Both HT and PDT are treatment modalities that
can greatly influence the tumour vasculature and thus, tumour
blood flow. In the literature, HT has been reported to have
distinctly heterogeneous effects on tumour blood flow, whereby
this variability may be at least partially explained by the use of
different heating protocols in tumours with different histologies. In
the DS-sarcoma used in the present study, HT has previously been
shown to have a bimodal effect on tumour blood flow with an
initial increase in perfusion of up to 20% being followed by a
decrease down to 25% of pretreatment values (Kelleher et al, 1995).
Microvascular damage, which in some instances can even result in
blood flow stasis, has frequently been seen following PDT (Reed
et al, 1988; Fingar et al, 2000; Dolmans et al, 2002). Investigations
of the effects of ALA-PDT on the microcirculation have shown
decreases in perfusion in a number of experimental and human
tumours (Roberts et al, 1994; Svanberg et al, 1996; Herman et al,
1999) and in normal tissue (Leveckis et al, 1995). However, in
some tumour models, a lack of significant changes in blood flow
has also been reported (Herman et al, 1999). In light of these
possible vascular effects of both HT and ALA-PDT, tumours were
excised directly after treatment and their in vitro growth behaviour
monitored so that the extent of direct tumour cell damage by each
of the treatments could be assessed. Theoretically, were the effects
of the single or combined treatments purely due to vascular
damage, then a decrease in cell viability as assessed immediately
after treatment should not be seen. At the same time, the growth of
tumour cells following excision should not be affected. In this
study, however, both HT and ALA-PDT were seen to result in
decreased cell viability after treatment. This effect was even more
pronounced following ALA-PDTþHT and therefore suggests that
vascular damage alone is not responsible for the tumour cure seen
in vivo. Additionally, the fact that a growth delay was observed for
the surviving cells suggested that these cells, while still being
viable, were nevertheless affected by treatment. Despite the low
percentage of tumour cells remaining viable after ALA-PDTþHT
treatment, subsequent in vitro growth was seen with cells of all
excised tumours, a finding that somewhat conflicts with the in vivo
results. One reason for this may be that ALA-PDTþHT treatment,
while not killing all tumour cells during treatment, may cause
delayed cell death as a result of vascular damage. Alternately, the
ALA-PDTþHT treatment may reduce the number of viable
tumour cells to the extent that the host immune system is able
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to effectively trigger an immune response through the generation
of tumour-sensitised immune cells (Korbelik and Dougherty,
1999). A similar effect has been suggested for HT, which can
enhance the host antitumour immune response via the expression
of heat-shock proteins (Ito et al, 2001). The immune system could
therefore be stimulated by both components of the ALA-PDTþHT
treatment. Thus, although direct tumour cell kill appears to play a
major role in the ALA-PDTþHT effect, immunological and/or
vascular effects may explain the differences seen between the in
vitro and in vivo findings in this study. Other potential factors that
might be involved in the pronounced potentiation of the
antitumour effects seen are a concerted action of PDT and HT
on certain proteins or supramolecular structures (Prinsze et al,
1991) or a conversion of PDT-induced repairable lesions to
irreparable lesions upon HT treatment (Chen et al, 2001).
Additionally, increased lactic acid formation during HT, as has
already been reported for this tumour model (Kelleher et al, 1995),
may also result in a lower pH in tumour tissue, and since acidosis
has been found to enhance the efficacy of ALA-PDT in vitro (Wyld
et al, 1998), such metabolic changes within the tumour tissue may
play a role in the effects of ALA-PDTþHT.
In conclusion, a tumour therapy is described, which is based on
ALA-PDT being carried out simultaneously with 431C HT using a
single, easily applied, nonlaser radiation source. This combined
treatment was found to be more effective than the sum of its
components, an effect which appears not to be based solely on
vascular damage. Investigations into the mechanisms underlying
the effects of ALA-PDTþHT are to be carried out to more clearly
define the interaction of the therapy components.
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